vs
Q32 Bio Inc.(QTTB)与REZOLVE AI PLC(RZLV)财务数据对比。点击上方公司名可切换其他公司
Q32 Bio Inc.的季度营收约是REZOLVE AI PLC的1.6倍($1.9M vs $1.2M),Q32 Bio Inc.净利率更高(2991.2% vs -1078.8%,领先4070.0%)
Q32 Bio Inc.是一家处于临床阶段的生物技术企业,专注于研发针对自身免疫疾病、炎症性疾病及罕见免疫类疾病的靶向抗体免疫疗法,面向有未满足医疗需求的患者群体,核心业务覆盖北美与欧洲市场。
REZOLVE AI PLC是总部位于英国的科技企业,开发人工智能驱动的移动互动与即时交易平台,支持用户直接从音频、视频、印刷内容中完成购买,服务欧洲、北美及部分亚太市场的零售、消费品与媒体客户。
QTTB vs RZLV — 直观对比
营收规模更大
QTTB
是对方的1.6倍
$1.2M
净利率更高
QTTB
高出4070.0%
-1078.8%
损益表 — Q4 FY2025 vs Q2 FY2025
| 指标 | ||
|---|---|---|
| 营收 | $1.9M | $1.2M |
| 净利润 | $57.7M | $-13.0M |
| 毛利率 | — | — |
| 营业利润率 | — | -808.4% |
| 净利率 | 2991.2% | -1078.8% |
| 营收同比 | — | — |
| 净利润同比 | 506.9% | — |
| 每股收益(稀释后) | $4.70 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比,按日历期对齐,财年错位的公司也能正确匹配
营收
QTTB
RZLV
| Q4 25 | $1.9M | — | ||
| Q3 25 | $-220.0K | — | ||
| Q2 25 | $-284.0K | $1.2M | ||
| Q1 25 | $-371.0K | — | ||
| Q4 24 | $0 | — | ||
| Q3 24 | $0 | — | ||
| Q2 24 | $0 | — | ||
| Q1 24 | $0 | — |
净利润
QTTB
RZLV
| Q4 25 | $57.7M | — | ||
| Q3 25 | $-7.4M | — | ||
| Q2 25 | $-9.5M | $-13.0M | ||
| Q1 25 | $-11.0M | — | ||
| Q4 24 | $-14.2M | — | ||
| Q3 24 | $-17.6M | — | ||
| Q2 24 | $-17.0M | — | ||
| Q1 24 | $1.0M | — |
营业利润率
QTTB
RZLV
| Q4 25 | — | — | ||
| Q3 25 | 3444.1% | — | ||
| Q2 25 | 3229.2% | -808.4% | ||
| Q1 25 | 3296.0% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
净利率
QTTB
RZLV
| Q4 25 | 2991.2% | — | ||
| Q3 25 | 3358.6% | — | ||
| Q2 25 | 3341.2% | -1078.8% | ||
| Q1 25 | 2973.3% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
每股收益(稀释后)
QTTB
RZLV
| Q4 25 | $4.70 | — | ||
| Q3 25 | $-0.60 | — | ||
| Q2 25 | $-0.78 | — | ||
| Q1 25 | $-0.90 | — | ||
| Q4 24 | $2.63 | — | ||
| Q3 24 | $-1.46 | — | ||
| Q2 24 | $-1.42 | — | ||
| Q1 24 | $-6.33 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | ||
|---|---|---|
| 现金及短期投资手头流动性 | $48.3M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $42.0M | $-14.3M |
| 总资产 | $61.8M | $80.1M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势,按日历期对齐
现金及短期投资
QTTB
RZLV
| Q4 25 | $48.3M | — | ||
| Q3 25 | $49.0M | — | ||
| Q2 25 | $54.8M | — | ||
| Q1 25 | $65.5M | — | ||
| Q4 24 | $78.0M | — | ||
| Q3 24 | $89.1M | — | ||
| Q2 24 | $97.7M | — | ||
| Q1 24 | $115.5M | — |
股东权益
QTTB
RZLV
| Q4 25 | $42.0M | — | ||
| Q3 25 | $-18.4M | — | ||
| Q2 25 | $-12.2M | $-14.3M | ||
| Q1 25 | $-4.0M | — | ||
| Q4 24 | $5.7M | — | ||
| Q3 24 | $18.3M | — | ||
| Q2 24 | $33.5M | — | ||
| Q1 24 | $48.8M | — |
总资产
QTTB
RZLV
| Q4 25 | $61.8M | — | ||
| Q3 25 | $57.8M | — | ||
| Q2 25 | $66.1M | $80.1M | ||
| Q1 25 | $79.1M | — | ||
| Q4 24 | $92.3M | — | ||
| Q3 24 | $104.5M | — | ||
| Q2 24 | $124.2M | — | ||
| Q1 24 | $152.3M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | ||
|---|---|---|
| 经营现金流最新季度 | $-6.2M | $-4.9M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | -0.11× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势,按日历期对齐
经营现金流
QTTB
RZLV
| Q4 25 | $-6.2M | — | ||
| Q3 25 | $-4.2M | — | ||
| Q2 25 | $-10.7M | $-4.9M | ||
| Q1 25 | $-12.5M | — | ||
| Q4 24 | $-11.4M | — | ||
| Q3 24 | $-19.5M | — | ||
| Q2 24 | $-22.2M | — | ||
| Q1 24 | $-14.6M | — |
自由现金流
QTTB
RZLV
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-11.4M | — | ||
| Q3 24 | $-19.6M | — | ||
| Q2 24 | $-22.2M | — | ||
| Q1 24 | — | — |
资本支出强度
QTTB
RZLV
| Q4 25 | — | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金转化率
QTTB
RZLV
| Q4 25 | -0.11× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -14.14× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图